One retrospective analysis showed a relationship between increased ERCC1 mRNA or protein expression levels and resistance to cisplatin-based chemotherapy in many types of advanced tumors, including non-small cell lung cancer (NSCLC) [21,22], esophageal cancer [23], and colon cancer [24,25,26,27]. Here, ERCC1 is linked to non-small cell lung carcinoma.